<DOC>
	<DOCNO>NCT00851435</DOCNO>
	<brief_summary>The objective open study ass safety , tolerability , pharmacokinetics clinical outcome patient HAP cause Pseudomonas aeruginosa serotype O11 three separate administration KBPA-101 every third day addition standard care antibiotic treatment .</brief_summary>
	<brief_title>Safety Pharmacokinetics KBPA-101 Hospital Acquired Pneumonia Caused O11 Pseudomonas Aeruginosa</brief_title>
	<detailed_description>Hospital acquire pneumonia ( HAP ) pneumonia occur 48 hour hospital admission . HAP occur patient conventional hospital ward intensive care unit ( ICU ) , associated mechanical ventilation , know Ventilator Associated Pneumonia ( VAP ) . VAP common infection intensive care unit represent 82 % HAP case . Pseudomonas aeruginosa one frequent pathogens involve ICU-HAP despite adequate treatment crude mortality remain high 70 % case .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Ventilator-Associated</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female ≥ 18 year age Patients intensive care management hospital acquire pneumonia Microbiological diagnosis P. aeruginosa serotype O11 HAP low respiratory tract specimen ( BAL miniBAL ) presence new progress pulmonary infiltrate , plus one three follow criterion : ) fever great 38ºC , b ) WBC great 10,000/mm3 , c ) purulent sputum In nonintubated patient confirm microbiological diagnosis P. aeruginosa serotype O11 HAP endotracheal aspirate ( ETA ) modify clinical pulmonary infection score ( CPIS ) high 6 point Patient expect survive long 72 hour Written inform consent provide patient relative designate trust person Use investigational drug within 30 day precede first dose KBPA101 , plan use study safety followup period Existence surgical medical condition might render patient unduly susceptible possible toxicity monoclonal antibody , include septic shock unstable hemodynamics , Patients know complement deficiency associate systemic lupus erythematosus , paroxysmal nocturnal hemoglobinuria , hereditary angioedema , membranoproliferative glomerulonephritis , collagen vascular disease , autoimmune hepatitis , primary biliary cirrhosis , scleroderma , recurrent Neisserial infection Confirmed Human Immunodeficiency Virus ( HIV ) infection Transplant patient and/or simultaneous treatment systemic immunosuppressive drug . Patients know liver function deficiency , e.g . associate liver cirrhosis ( Child Pugh B C ) acute hepatitis Administration poly monoimmunoglobulins within three month precede first dose study drug plan administration study period Neutropenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Pneumonia</keyword>
	<keyword>Nosocomial pneumonia</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Hospital-Acquired Pneumonia</keyword>
</DOC>